BioHelix Corporation is developing a rich portfolio of proprietary
technologies for nucleic acid analysis and molecular diagnostics
through internal research and in-licensing of novel technology.
Currently, we have two unique isothermal amplification platforms:
the target based-Helicase Dependant Amplification platform (HDA);
and the primase-based Whole Genome Amplification platform (pWGA).
In addition, we have also developed a series of amplification enhancer
reagents targeted to improve all types of nucleic acid amplification
BioHelix's proprietary nucleic acid technology platforms have several
advantages; including high sensitivity & specificity, ease-of-use,
and low-cost. The company initially aims to commercialize assays
that target the infectious disease market. With the discovery of
novel biomarkers fueling the growth of the personalized medicine
field, BioHelix's technology platforms are well positioned to capture
these emerging markets with our simple, rapid screening tests capable
of being performed at the point-of-care (POC) and; potentially even
in the home.